Trials / Recruiting
RecruitingNCT07185035
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A single-center, open-label dose-escalation design to evaluate the safety and efficacy of KN5001 in patients with pulmonary nodules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KN5001 | Subjects will receive KN5001 on day0, 3, and 6. Multiple Doses of KN5001 will infused using the "3 + 3" dose-escalation strategy. |
Timeline
- Start date
- 2025-09-20
- Primary completion
- 2026-09-20
- Completion
- 2027-09-20
- First posted
- 2025-09-22
- Last updated
- 2025-12-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07185035. Inclusion in this directory is not an endorsement.